US OKs Refocus' presbyopia implant trials:
This article was originally published in Clinica
Executive Summary
The US FDA has given Refocus the go-head to start phase II trials of its implant system for treating presbyopia (long-sightedness). The Dallas, Texas firm plans to test its scleral spacing procedure in 100 patients at 10 sites across the US.